{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.8","value":"179"},{"groupId":"OG001","spread":"58.1","value":"205"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)","title":"Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"μg/mL"}